A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer

  • J. P. Burke
  • , C. Power
  • , T. F. Gorey
  • , F. Flanagan
  • , M. J. Kerin
  • , M. R. Kell

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

15 Citations (Scopus)

Abstract

Aims: To compare prognostic factors in screen detected breast cancer (SDBC) and symptomatically presenting breast cancer (SBC). Methods: Data were examined on 100 SDBC and 100 SBC. Multiple clinical patient factors were assessed including histopathological features. Using the Gail model each patient's risk of developing breast cancer was calculated and these data were examined for differences between groups. Results: There was no difference in the mean age of patient presentation or in the risk of breast cancer development between groups (2.2% vs. 2.2%, SDBC vs. SBC, actuarial risk of cancer at 5 years). SDBC patients had a significantly lower grade (1.95 vs. 2.44, SDBC vs. SBC, P < 0.05), a smaller size of tumour (15.4 mm vs. 29.3 mm, SDBC vs. SBC, P < 0.05) and a higher rate of oestrogen (94% vs. 81%, P < 0.05) and progesterone (75% vs. 52%, P < 0.05) receptor positivity. When compared using the Nottingham Prognostic Index, SDBC was associated with a better prognosis (r = -0.444, P < 0.001). Conclusions: Though both groups have similar demographics and risk, SDBC patients appear to have more favourable prognostic features. This has implications for the application of systemic therapy in breast cancer and supports the observation that SDBC is a more indolent form of disease.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2008
Externally publishedYes

Keywords

  • Breast
  • Comparative study
  • Neoplasm
  • Prognosis
  • Risk factors
  • Screening mammography

Fingerprint

Dive into the research topics of 'A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer'. Together they form a unique fingerprint.

Cite this